MRKR News and Press, Marker Therapeutics Inc. From 08/11/22

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! Earnings reports, sale rumors, and an offer to t...

HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...

Marker Therapeutics press release (NASDAQ:MRKR): Q1 GAAP EPS of -$0.12 beats by $0.01. Revenue of $964.32M. For further details see: Marker Therapeutics GAAP EPS of -$0.12 beats by $0.01, revenue of $964.32M

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. ...

HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, toda...

Marker Therapeutics (NASDAQ:MRKR) signed a services agreement with Wilson Wolf Manufacturing related to making of cell therapies. Under the agreement, Marker will get an $8M upfront payment from Wilson in exchange for services related to Marker’s expertise in manufacturing ce...

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today a...

Marker Therapeutics press release (NASDAQ:MRKR): FY GAAP EPS of -$0.55 beats by $0.02. Revenue of $1.24M (+163.8% Y/Y). For further details see: Marker Therapeutics GAAP EPS of -$0.55 beats by $0.02, revenue of $1.24M

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinica...